Core One Labs’ Vocan Successfully Converts Psilocin Precursor into Psilocybin
Core One Labs Inc. (OTCQB:CLABF) announced that its subsidiary Vocan Biotechnologies has successfully converted a psilocin precursor into psilocybin using enzymatic methods. This process yielded approximately 160 grams of contaminant-free psilocybin from 220 grams of psilocin precursor. The company anticipates increased production capabilities with new equipment and a GMP-compliant contract manufacturer. Core One aims to contribute to the growing field of psychedelic medicine for mental health treatment, emphasizing their commitment to enhancing shareholder value.
- Successful conversion of psilocin to psilocybin, achieving 100% success rate.
- Production of 160 grams of contaminant-free psilocybin showcases effective technology.
- Anticipation of increased yields with new production equipment.
- Commitment to advancing psychedelic medicines enhances shareholder value prospects.
- None.
VANCOUVER, BC / ACCESSWIRE / August 16, 2022 / Further to its press release dated August 12, 2022, Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6), (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. ("Vocan") has successfully employed enzymatic production methods to convert a chemically produced psilocin developed by the Company's recently acquired Awakened Biosciences Inc.'s ("Awakened"), into viable API psilocybin.
Awakened has produced approximately 220 grams (g) of a psilocin precursor which it can convert into a minimum of 125g of psilocin, the psychoactive ingredient in psilocybin. This, using Vocan's production technology, can be transformed into, about 160 g of contaminant free psilocybin, at a
The successful test batch results and the quantity and purity of psilocybin being produced in Vocan's research purposed lab facility, within such a short period of time, emphasizes the efficiency of their production technology. The Company anticipates that furnishing Vocan's current lab facilities with small scale production purposed equipment will result in significantly increased yields, and further anticipates mass production capabilities with the engagement of a GMP compliant contract development and manufacturing organization (CDMO).
"The renaissance of psychedelics medicine as an alternative means to addressing mental health afflictions has been making significant strides in the last decade, and I am very confident when I say that Core One is doing its part from an early onset," stated Joel Shacker, Core One CEO.
"Our team of scientists, and their groundbreaking collaborations are putting Core One ‘on the map'; not only as leading innovators in psychedelics research and development, but also as a ‘one stop shop' for patients, physicians and researchers, alike. With a growing body of research, and an increased openness to evaluate psychedelic treatments on its merits, rather than on historic myths and misnomers, Core One feels that demand for access to psychedelic medicines and psychedelic-assisted treatments will also continue increase. We are committed to meeting the anticipated demands and by doing so we will continue to grow shareholder value."
About Core One Labs Inc.
Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.
The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.
Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its
In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-866-347-5058
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
SOURCE: Core One Labs Inc.
View source version on accesswire.com:
https://www.accesswire.com/712229/Core-One-Labs-Vocan-Successfully-Converts-Psilocin-Precursor-into-Psilocybin
FAQ
What recent achievement did Core One Labs (CLABF) announce regarding psilocybin production?
How much psilocin precursor was converted into psilocybin by Core One Labs?
What does Core One Labs (CLABF) plan for future production of psilocybin?
What is the significance of Core One Labs' achievement in the psychedelic medicine field?
